Skip to main content
Explore URMC

menu

Bladder Cancer: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Research Question:
What are the good and bad effects of using the Tokyo-172 version of BCG with the currently used BCG LIVE (TICE® BCG) version on people with bladder cancer receiving BCG in the bladder and what are the good and bad effects of adding a BCG vaccination (given under the skin) in addition to placing BCG in only the bladder?

Basic Study Information

Purpose:
This study has 3 study groups; Group 1 will receive the usual BCG LIVE (TICE® BCG) version of BCG in the bladder, Group 2 will receive BCG in the bladder but it will be the Tokyo-172 version of BCG instead of the BCG LIVE (TICE® BCG) version, and Group 3 will receive a vaccination as an injection under the skin with the Tokyo-172 version of BCG followed by receiving the Tokyo-172 version in the bladder. A computer will assign you to treatment groups in the study by chance. This is done by chance because no one knows if one study group is better or worse than the others. Neither you nor your doctor will be able to choose your treatment.

Location: Cancer Center - Urology
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03091660?term=S1602&rank=1
Study Reference #: CGUB17077

Lead Researcher (Principal Investigator)

Lead Researcher: Edward Messing

Study Contact Information

Study Coordinator: Dee Doyle
Phone: (585) 275-0126
Email: dee_doyle@URMC.Rochester.edu

Additional Study Details

Return to Search